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The transporter associated with antigen processing (TAP) delivers the viral proteolytic products generated by the proteasome in
the cytosol to the endoplasmic reticulum lumen that are subsequently recognized by cytotoxic T lymphocytes (CTLs). However,
several viral epitopes have been identified in TAP-deficient models. Using mass spectrometry to analyze complex human leuko-
cyte antigen (HLA)-bound peptide pools isolated from large numbers of TAP-deficient vaccinia virus-infected cells, we identified
11 ligands naturally presented by four different HLA-A, HLA-B, and HLA-C class I molecules. Two of these ligands were pre-
sented by two different HLA class I alleles, and, as a result, 13 different HLA-peptide complexes were formed simultaneously in
the same vaccinia virus-infected cells. In addition to the high-affinity ligands, one low-affinity peptide restricted by each of the
HLA-A, HLA-B, and HLA-C class I molecules was identified. Both high- and low-affinity ligands generated long-termmemory
CTL responses to vaccinia virus in an HLA-A2-transgenic mouse model. The processing and presentation of two vaccinia virus-
encoded HLA-A2-restricted antigens took place via proteasomal and nonproteasomal pathways, which were blocked in infected
cells with chemical inhibitors specific for different subsets of metalloproteinases. These data have implications for the study of
the effectiveness of early empirical vaccination with cowpox virus against smallpox disease.
The eradication of smallpox, a disease caused by variola majorvirus, was made possible by early empirical, cross-protective
vaccination with cowpox virus and later through the massive
worldwide production and administration of vaccinia virus
(VACV) vaccines (18). The Orthopoxvirus vaccinia virus is a
widely used tool for research and vaccine development (47), and
recent concerns about bioterrorism and emerging infectious dis-
eases have elicited renewed interest inVACVand other poxviruses
(31). Vaccination induces a strong humoral response leading to
viral clearance, and the role of cellular responses in this cross-
protection is well documented (21, 56). In recent years, studies
using both vaccinated humans and human histocompatibility
complex (HLA)-transgenic mouse models have allowed the iden-
tification of more than 70 VACV-derived epitopes restricted by
various HLA molecules (reviewed in references 30 and 32).
In cellular immunity, recognition and killing of infected cells
by CD8 cytolytic T lymphocytes (CTLs) first require viral pro-
teins to be proteolytically degraded (73). Antigen (Ag) processing
generates short peptides that are translocated to the endoplasmic
reticulum (ER) lumen by the transporter associated with antigen
processing (TAP) and then assembled with a newly synthesized
2-microglobulin and HLA class I heavy chain. Despite initial
assumptions that the multicatalytic and ubiquitous proteasome
was the only protease fully capable of generating peptide ligands
for presentation on HLA class I molecules, several studies have
demonstrated that a growing number of alternative pathways con-
tribute to endogenous antigen processing (reviewed in references
13 and 27).
Individuals withmutations in the TAP gene that generate non-
functional TAP complexes have been previously described (re-
viewed in reference 9). Patients with this HLA class I deficiency
may appear asymptomatic for long periods of their lives. TAP-
deficient (TAP) patients do not seem particularly susceptible to
viral infections or neoplasms. Therefore, their immune systems
must be reasonably efficient, and antibodies (Abs), NK cells,
CD8  T cells, and the reduced cytolytic CD8  T subpop-
ulation that is specific for TAP-independent antigensmay all con-
tribute to immune defenses that protect against severe viral infec-
tions in such individuals. In addition, several strains of viruses,
including cowpox virus (1), have found ways to obstruct TAP
expression or function in order to prevent CTLs from identifying
infected cells (reviewed in reference 36); therefore, the TAP-
independent pathwaysmust be important for killing cells infected
with these viruses. The identification of TAP-independent
epitopes that are conserved among orthopoxviruses could also be
relevant to the study of the mechanisms of early empirical vacci-
nation against smallpox disease as performed with cowpox virus.
Although TAP-independent viral epitopes are known (re-
viewed in reference 36), there has been a marked absence of me-
thodical studies of TAP-independent epitopes and ligands re-
stricted by different HLA molecules in cells infected with a single
virus. Moreover, in all previous studies, very limited antigen pro-
cessing capacity in TAP-deficient cells has been reported. There-
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fore, is only one TAP-independent ligand or epitope restricted by
a single HLA molecule exposed on the cell membrane surface, as
suggested by these studies? Conversely, could a TAP-deficient cell
simultaneously bind several viral ligands to different HLA mole-
cules? We are interested in the identification of viral ligands pre-
sented by several common HLA antigens in TAP-deficient in-
fected cells. Using immunoproteomic analysis, we comparedHLA
ligands isolated from large numbers of healthy or VACV-infected
cells. This study identified 11 TAP-independent, naturally pro-
cessed ligands from eight different VACVproteins in infected cells
that were mostly conserved among the members of theOrthopox-
viridae family, including cowpox virus.
MATERIALS AND METHODS
Mice.H-2 class I knockout HLA-A*0201-transgenic mice (20) were bred
in our animal facilities in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals and Spanish gov-
ernment regulations (accreditation 28079-34A). The protocol was ap-
proved by the Committee on the Ethics of Animal Experiments of the
Institute of Health “Carlos III” (permit PI-283). All surgery was per-
formed under conditions of sodium pentobarbital anesthesia, and all ef-
forts were made to minimize suffering.
Cell lines. T2 cells, a line of TAP-deficient human cells that express
HLA-A2,HLA-B51, andHLA-Cw1 class Imolecules on their surface (57),
were transfected with HLA-B27 (a gift from David Yu, University of Cal-
ifornia, Los Angeles, CA). The mouse cell lines RMA (TAP positive
[TAP]) and RMA-S (TAP) were transfected with HLA-A*0201 12
domains, and the mouse H-2Db 3 transmembrane and cytoplasmic do-
mains have been previously described (52). The RMA-S transfectant cells
expressingHLA-B*2705 have been previously described (66). All cell lines
were cultured in RPMI 1640 medium supplemented with 10% fetal bo-
vine serum (FBS) and 5 M -mercaptoethanol (-ME).
Synthetic peptides. Peptides were synthesized in a peptide synthesizer
(model 433A; Applied Biosystems, Foster City, CA) and purified by
reverse-phase high-performance liquid chromatography (HPLC). The
correct molecular mass of the peptides was established by matrix-assisted
laser desorption ionization–time of flight mass spectrometry (MALDI-
TOF MS), and their correct composition was determined by quadrupole
ion trap micro-HPLC.
Inhibitors. Brefeldin A (BFA) and all protease inhibitors were pur-
chased from Sigma-Aldrich, except for leupeptin (LEU) (Amersham-
UBS), pepstatin (PEPST) (BoehringerMannheim), Z-VAD.fmk (Enzyme
System Products, Livermore, CA), (z-LL)2 ketone (Merck), and lactacys-
tin (E. J. Corey, Harvard University). The specificity and activity of all
inhibitors used in this study are summarized in Table 1. For control of
activity of the protease inhibitors, RMA-HLA-A*0201 cells (1 108) were
disrupted by sonication for 15 min at 4°C and centrifuged as previously
reported (40). A supernatant aliquot corresponding to 1  107 cells was
directly frozen (nondegraded control). Equivalent aliquots were incu-
bated in the presence of individual inhibitors at 200M, and digestion by
cellular proteases was allowed to proceed for 5 days at 37°C in phosphate-
buffered saline (PBS). Inhibitors were renewed daily. A sample incubated
without inhibitors was used as the degraded control. After sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) separation
and Coomassie blue staining of these samples, the overall protein content
of each lane was quantitated by densitometry using the TINA 2.09e pro-
gram (Isopenmegeräte GmbH, Germany). Percent inhibition of protein
degradation caused by each inhibitor was calculated as follows: 100 
(sample with inhibitor degraded sample)/(nondegraded sample de-
graded sample).
Infection of the T2-B27 cell line by VACV. A total of 1 109 to 3
109 T2-B27 cells were infected with VACV at a multiplicity of infection of
10 PFU/cell in 10ml, incubated for 2 h at 37°C, and thenwashed. The cells
were then cultured for 24 h and stained with Omnitope antiserum-
fluorescein isothiocyanate (FITC), which recognizes VACV-purified viri-
ons. Samples were analyzed by fluorescence-activated cell sorting (FACS).
Later, the cells were frozen.
Isolation of HLA-bound peptides. HLA-bound peptides were iso-
lated from 4  1010 healthy or VACV-WR-infected T2-B27 transfectant
cells. Cells were lysed in 1% CHAPS (3-[(3-cholamidopropyl)-dimethyl-
ammonio]-1-propanesulfonate; Sigma)–20 mM Tris-HCl buffer–150
mM NaCl (pH 7.5) in the presence of a protease inhibitor cocktail (24).
HLA-peptide complexes were isolated via affinity chromatography of the
soluble fraction of cell extracts with the following monoclonal antibodies
(MAbs), used sequentially: PA2.1 (anti-HLA-A2) (51), ME1 (anti-HLA-
B27) (14), and W6/32 (specific for a monomorphic HLA class I determi-
nant) (6) (Fig. 1). HLA-bound peptides were eluted at room temperature
with 0.1% aqueous trifluoroacetic acid (TFA), separated from the large
subunits, and concentrated using a Centricon 3 column (Amicon, Bev-
erly, MA) exactly as previously described (24).
Electrospray-ion trapmass spectrometry analysis. Peptide mixtures
recovered after the ultrafiltration step were concentrated usingMicro-Tip
reversed-phase columns (C18; Harvard Apparatus, Holliston, MA) (200
TABLE 1 Specificity and activity of the inhibitors used in this study
Inhibitor Abbreviation Specificity Reference(s) Concn
% Inhibition of
degradationa
Brefeldin A BFA Vesicle transport 48, 71 5 g/ml ND
Lactacystin LC Proteasome 19, 49 10 M ND
(z-LL)2 ketone z-LL2 Signal peptide peptidase 68, 69 100 M 13 4
Leupeptin LEU Trypsin-like proteases and cysteine proteases 65 100 M 38 18
Pepstatin PEPST Aspartic proteases 34, 65 100 M 50 5
1-10 Phenanthroline PHE Metalloproteases and caspase-1 34, 64 50 M ND
Leucinethiol LeuSH Metalloaminopeptidases, including ERAAP 61 30 M ND
Benzyl succynil acid BENZ Metallocarboxypeptidases A and B 34 100 M 10 8
Captopril CAPT ACEb and ACE-like proteases 34 100 M 25 2
Phosphoramidon PHOSP All bacterial metalloendopeptidases but few
of mammalian origin
22, 34 100 M 15 4
z-VAD.fmk z-VAD Caspases 62 100 M NDc
a The activity of these inhibitors was measured as their ability to prevent proteolytic degradation in cellular extracts by the method described in reference 40. The amount of protein
still present after incubation in the case of the degraded control sample was considered to represent 0% inhibition of degradation, and the nondegraded unincubated sample was
taken to represent 100 % inhibition. Data represent the means of the results of two independent experiments. The negative value indicates that there was enhanced degradation in
the presence of the compound. ND, not done.
b ACE, angiotensin-converting enzyme.
c The compound was found to block apoptosis (data not shown).
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l) (24). Each C18 tip was equilibrated with 80% acetonitrile–0.1% TFA,
washedwith 0.1%TFA, and then loadedwith the peptidemixture. The tip
was thenwashedwith an additional volumeof 0.1%TFA, and the peptides
were eluted with 80% acetonitrile–0.1% TFA. Peptide samples were then
concentrated to about 18 l using vacuum centrifugation (24).
HLA class I peptides immunoprecipitated with each HLA-specific
MAb were analyzed in three different HPLC runs by micro-liquid
chromatography-tandem MS (LC-MS/MS) using an Orbitrap XL mass
spectrometer (Thermo Electron, San Jose, CA) fitted with a capillary
HPLC column (Eksigent, Dublin, CA) (24). The peptides were resolved
on homemade Reprosil C18 capillary columns (75 m inner diameter)
(25) with a 7 to 40% acetonitrile gradient for 2 h in the presence of 0.1%
formic acid. The sevenmasses exhibiting the greatest intensity and single-,
double-, and triple-charge states were selected for fragmentation from
each full mass spectrum by collision-induced dissociation (CID).
Database searches. Sequest 3.31 software (Thermo-Fisher) (15) was
used for peak-list generation of the LC-MS/MS data. The peaks were
identified by using Proteome Discoverer 1.0 SP1 software (Thermo-
Fisher), combining the results obtained with Sequest 3.31 and Bioworks
Browser 3.3.1 SP1 (Thermo-Fisher) (15), and using the human and virus
parts of the NCBI database (January 2009), which included 656,486 pro-
teins. The search was not limited by enzymatic specificity, the peptide
tolerancewas set to 0.005Da, and the fragment ion tolerancewas set to 0.5
Da (24, 43). This search was not limited by any methodological bias (se-
lection of individual protein, use of HLA consensus-scoring algorithms,
etc.). Identified peptides were selected when the following criteria were
met: Sequest Xcorr 1.4 for singly, 2.2 for doubly, and 2.9 for triply
charged peptides; P(pep) less than 1 103; and mass accuracy of 0.005
Da (24, 43). When the MS/MS spectra fitted two or more peptides, only
the highest-scoring peptide was analyzed. No peptides were found in a
search of a reversed database. The purpose of the filtering criteria was to
identify candidate vaccinia virus peptideMS/MS scans for furthermanual
inspection to determine whether the MS/MS fragment ion fingerprint
matched the identified peptide sequence. In addition, the corresponding
synthetic peptidewasmade, and itsMS/MS spectrumwas used to confirm
the assigned sequence.
MHC-peptide stability assays. The following synthetic peptides were
used as controls in complex stability assays: KPNA2 (GLVPFLVSV,
HLA-A2 restricted) (23), influenza virus NP (SRYWAIRTR, HLA-B27
restricted) (67), hepatitis B virus (HBV) HBc19-27 (LPSDFFPSV, HLA-
B51 restricted) (8), cytomegalovirus (CMV) pp657-15 (RCPEMISVL,
HLA-Cw1 restricted) (33), and C4CON (QYDDAVYLK, HLA-Cw4 re-
stricted) (17). Either RMA-S transfectants or T2 cells expressing small
amounts of major histocompatibility complex (MHC) class I on the cell
surface were incubated at 26°C for 16 h in RPMI 1640 medium supple-
mentedwith 10%heat-inactivated fetal bovine serum (FBS). This allowed
the expression of empty MHC class I molecules (without antigenic pep-
tide) that are stable only at 26°C, and not at 37°C, on the cell membrane.
The cells were washed and incubated for 2 h at 26°C with various concen-
trations of peptide in the same medium. Afterward, the cells were kept at
37°C and collected after 4 h for flow cytometry analysis. This assay allows
for internalization of empty MHC class I molecules and can therefore
discriminate between bound and unbound peptides. HLA expression lev-
els were measured using monoclonal PA2.1 (anti-HLA-A2), monoclonal
ME1 (anti-HLA-B27), polyclonal H00003106-B01P (specific for HLA-B
class I molecules) (Abnova, Taipei, Taiwan), and polyclonal SC-19438
(specific for HLA-C class I molecules) (Santa Cruz Biotechnology, Santa
Cruz, CA) Abs as previously described (41). Samples were acquired on a
FACSCanto flow cytometer (BD Biosciences, San Jose, CA) and analyzed
using CellQuest Pro 2.0 software (BD Bioscience). Cells incubated with-
out peptides had peak fluorescence intensities close to those of back-
ground stainingwith secondaryAb alone. The fluorescence index (FI) was
calculated as the ratio of the mean channel fluorescence of the sample to
that of control cells incubated without the peptides. The binding of pep-
tides was also expressed as the 50% effective concentration (EC50), which
is the molar concentration of the peptides producing 50% of the maxi-
mum fluorescence obtained at a concentration range between 0.001 and
100 M.
Magnetic antigen cell separation (MACS). Mouse T lymphocytes
were isolated by the depletion of non-T CD8 cells (negative selection)
and the use of a T CD8a cell isolation kit (Miltenyi Biotec GmbH,
Gladbach, Germany) according to the manufacturer’s specifications. The
purity of the cell preparations recovered after negative selection was ver-
ified by fluorescence-activated cell sorting (FACS) and found to be higher
than 95% for CD8 T lymphocytes (3).
Ex vivo ICS. Intracellular cytokine staining (ICS) assays were per-
formed as described previously (58). Purified CD8 T lymphocytes were
obtained from HLA-A*0201-transgenic mice up to 30 days (memory)
postintraperitoneal (post-i.p.) infection with 1 107 PFU of VACV-WR,
stimulated for 2 h with either RMA or RMA-S HLA-A*0201 cells infected
with VACV-WR, and incubated overnight in the presence of BFA (5 g/
ml). Later, cells were incubated with FITC-conjugated anti-CD8 MAb
(ProImmune, Oxford, United Kingdom) for 30 min at 4°C, fixed with
Intrastain kit (DakoCytomation, Glostrup, Denmark) reagent A, and in-
cubated with phycoerythrin (PE)-conjugated anti-gamma interferon
(IFN-) MAb (BD PharMingen, San Diego, CA) in the presence of In-
trastain kit permeabilizing reagent B for 30 min at 4°C. Events were ac-
quired and analyzed as described for the MH-peptide stability assays.
T cell lines, cytotoxicity assays, and ICS. Polyclonal SIINFEKL or
VACV peptide-monospecific CTLs were generated by immunizing mice
i.p. with 1  107 PFU of VACV-OVA257-264 (encoding the miniprotein
MSIINFEKL) or VACV-WR, respectively, as previously described (40,
45). Splenocytes from immunized mice were restimulated in vitro with
mitomycin C-treated spleen cells pulsed with a 106 M concentration of
the respective peptide and cultured in alpha-minimal essential medium
(-MEM) supplemented with 10% FBS–1 107 M peptide–1% 2-ME.
Recombinant human interleukin-2 for the long-term propagation of
peptide-specific CTL lines was generously provided by Hoffmann-
LaRoche. The RMA-HLA-A*0201 cells were used as target cells in stan-
dard 4-h cytolytic assays (40).
ICS assays to detect the recognition of infected cells by polyclonal CTL
cell lines were performed as previously described (10). CTL lines were
stimulated for 4 h in the presence of BFA (5 g/ml) and target cells that
had been infected overnight with VACV or VACV-OVA257-264. When
protease inhibitors were used, all drugs were added 15 min before the
virus and kept at a 5-fold-higher concentration during the 1-h adsorption
FIG 1 Diagram of sequential immunoprecipitation. Healthy or VACV-infected T2-B27 transfectant cells (4 1010) were lysed. HLA-peptide complexes were
isolated via affinity chromatography of the soluble fraction of cell extracts with the following mAbs, used sequentially: PA2.1 (anti-HLA-A2), ME1 (anti-HLA-
B27), and W6/32 (specific for a monomorphic HLA class I determinant).
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period than throughout the infection. After the virus inoculum was
washed, the inhibitors were kept at the concentrations indicated for the
individual experiments. The inhibitors were not toxic at the indicated
concentrations, since they affected neither antigen presentation by either
of the A10L688-696 and A17L9-17 epitopes (see below) or VACV infection
when the Omnitope antiserum with specificity for VACV proteins from
purified virions (ViroStat Inc., Portland, ME) was used (see Fig. S1 in the
supplemental material). The ICS was performed with polyclonal CTL as
described for ex vivo ICS.
In vivo cytotoxicity assay. In vivo cytotoxicity assays were performed
as previously published (45). Spleens were obtained, erythrocytes were
removed, and HLA-A*0201 splenocytes were split into two populations
and labeled with either a high concentration (5 M) or a low concentra-
tion (0.5 M) of carboxyfluorescein succinimidyl ester(CFSE). After ex-
cess CFSE was removed by washing, CFSEhigh spleen cells were pulsed
with 106 M VACV peptides for 30 min at 37°C. Excess peptide was
washed at least twice, and CFSEhigh peptide-pulsed cells were mixed with
equal numbers of CFSElow cells. A total of 8 106 cells of the spleen cells
mixed suspension were i.p. injected into each HLA-A*0201-transgenic
mouse that had been left uninfected or had been i.p. infected with
VACV-WR (1  107 PFU) 7 days earlier. Two days later, the peritoneal
cavity was subjected to lavage, spleens were extracted, and the cells were
analyzed by flow cytometry using a FACSCanto flow cytometer to mea-
sure in vivo killing. Data were analyzed using CellQuest Pro 2.0 software.
Specific lysis was calculated as previously published (45) according to the
following formula: [1 (ratio unprimed/ratio primed) 100], where the
ratio unprimed values represent % CFSElow/% CFSEhigh cells remaining
in control uninfected recipients and the ratio primed values represent %
CFSElow/% CFSEhigh cells remaining in experimentally infected recipi-
ents.
RESULTS
VACV-specific CD8 T cells recognize TAP-deficient HLA-
A*0201-transfected cells. As the first step in the study of TAP-
independent HLA-restricted responses to vaccinia virus, HLA-
A*0201-transgenicmicewere immunizedwith the virus.Next, the
VACV-specific CD8 response was evaluated using intracellular
cytokine staining (ICS) assays. A strong ex vivo response (i.e.,
50.1% 9.4%of CD8 cells secreted IFN-) specific for this virus
was detected in TAP-positive (TAP) target cells (Fig. 2, left
panel). Additionally, a small fraction of VACV-specific CD8 T
lymphocytes recognized infected TAP-deficient cells (3.8 0.8%
of CD8 cells secreted IFN-) (Fig. 2, right panel). These data
indicate the existence of a TAP-independent antigen-processing
pathway(s) of some vaccinia virus epitopes in infected cells that
could be recognized by specific CD8 T lymphocytes.
Physiological processing generates three different viral
HLA-A2 ligands in human TAP-deficient vaccinia virus-
infected cells. HLA-A2-bound peptide pools were isolated from
large numbers of either healthy or VACV-infected human TAP-
deficient cells (110  20 mean fluorescence intensity [MFI] in
VACV-infected cells versus 15 5 in healthy cells stained with an
anti-VACV antiserum). These peptide mixtures were subse-
quently separated by reverse-phase HPLC and analyzed by mass
spectrometry. According to the results observed with bioinfor-
matics tools, three fragmentation spectra present in the VACV-
infected HLA-A2-bound peptide pool, but absent from the con-
trol uninfected pool, were resolved with high-confidence
parameters as peptides of vaccinia virus proteins. A human pro-
teome database search failed to identity any of these spectra as
human protein fragments, confirming the viral origin of these
peptides. The first ion peak, with anm/z of 926.4, was assigned to
the viral amino acid sequenceMLDDFSAGA, spanning residues 9
to 17 of the A17L protein of vaccinia virus (see Fig. S2 in the
supplemental material, upper panel). In addition, two different
ion peaks atm/z 974.6 and 514.8 were assigned to peptides of the
same viral protein. These ion peaks corresponded to the SPEGE
ETII peptide (see Fig. S2 in the supplemental material, middle
panel) and ILDRIITNA peptide (see Fig. S2 in the supplemental
material, lower panel), which span residues 614 to 623 and resi-
dues 688 to 696, respectively, of the A10L protein. Virtually all
significant fragments of the threeMS/MS spectra were assigned as
daughter ions of the putative peptidic sequences (see Fig. S2 in the
supplemental material). This theoretical assignment was con-
firmed by determination of identity with the MS/MS spectrum of
the corresponding synthetic peptide (see Fig. S2 in the supple-
mental material). Therefore, these results indicate that a total of
three TAP-independent HLA-A2 ligands were endogenously pro-
cessed and presented in the VACV-infected cells.
Binding affinity of TAP-independent vaccinia virus ligands
for the A*0201 molecule. The classical anchor motifs for HLA-
A*0201 binding, Leu or Met at position 2 (P2) and aliphatic
C-terminal residues (SYFPEITHI database; http://www.syfpeithi
.de [54]), were present in two of the three TAP-independent viral
ligands detected. In contrast, the A10L614-623 ligand presented Pro
at P2, although it coimmunoprecipitated with an HLA-A2-
specific MAb and thus could have represented an unusual HLA-
A2-restricted ligand. To confirm that HLA-A*0201 was the MHC
class I molecule that presented these ligands, MHC-peptide com-
plex stability assays were performed using TAP-deficient RMA-S
cells transfected with the HLA-A*0201 molecule (Fig. 3). The two
viral ligands with HLA-A2 anchor motifs, A10L688-696 and
A17L9-17, bound to HLA-A*0201 class I molecules with EC50s in
the range commonly found among other natural high-affinity li-
gands (Fig. 3B). In contrast, HLA affinity for the A10L614-623 li-
gand was substantially lower, as the absence of HLA-A2 anchor
motifs suggested; therefore, this peptide must be considered a
low-affinity ligand. These data confirm that all ligands detected in
vaccinia virus-infected cells were endogenously presented in asso-
ciation with the A*0201 molecule.
Three viral HLA-B*2705 ligands were endogenously pro-
cessed in human TAP-deficient vaccinia virus-infected cells. To
date, about 60 human TAP-independent MHC class I ligands are
FIG 2 Recognition of TAP and TAP cell lines by VACV-specific CD8 T
lymphocytes. HLA-A0201 TAP cells (RMA; left panel) and TAP cells
(RMA-S; right panel) were infected with VACV at amultiplicity of infection of
40 PFU/cell and analyzed by ICS for CD8 T cell activation. The results are
calculated as the means  standard deviations (SD) of the results of three or
four independent experiments. , P 0.0001.
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known (36, 70), and these are mostly restricted by HLA-A2 and
derived from the cleavage of signal sequences generated by the
signal peptidase (SPase) complex. The A*0201-restricted CTL
epitopes of vaccinia virus that we detected in TAP-deficient cells
could therefore be exceptional, and TAP-independent antigen-
processing pathways might be unable to generate vaccinia virus
peptides that could bind to other HLA class I molecules. HLA-
B27, which was previously described as an allele with high TAP
dependency (2), was used to obtain peptide pools from either
healthy or VACV-infected TAP-deficient cells, as used to identify
the HLA-A*0201 ligands. Again, three fragmentation spectra
present in theVACV-infected,HLA-B27-bound peptide pool, but
absent from the control uninfected pool, were also resolved as
peptides of vaccinia virus proteins. The human proteome data-
base search failed to identify these spectra as representing human
protein fragments, confirming the viral origin of these HLA-B27-
bound peptides. The first ion peak, with an m/z of 428.8, was
assigned to the viral amino acid sequence SRGYFEHMKK, which
spans residues 867 to 876 of the A10L protein of vaccinia virus (see
Fig. S3 in the supplemental material, upper panel), indicating that
antigen processing of this protein could generate several viral li-
gands bound to two different HLA class I molecules. The second
ion peak, at m/z 567.6, was assigned to the peptidic sequence YR
LQGFTNAGIVAYK (see Fig. S3 in the supplemental material,
middle panel), which spans residues 16 to 30 of the K2L protein.
Finally, the third ion peak, atm/z 471.8, corresponded to a WQT
MYTN peptide (see Fig. S3 in the supplemental material, lower
panel), which spans residues 53 to 59 of the B8R protein. Figure S3
in the supplemental material shows that all significant fragments
of these threeMS/MS spectrawere assigned as daughter ions of the
putative peptidic sequences. As HLA-A2 ligands, these assign-
ments were confirmed by identity with the MS/MS spectrum of
the corresponding synthetic peptide (see Fig. S3 in the supple-
mental material). In addition, the K2L16-30 ligand was also identi-
fied as a molecular ion atm/z2 (see Fig. S5 in the supplemental
material). Collectively, these results indicate that similar numbers
of TAP-independent ligands were endogenously processed and
presented by HLA-A2 and HLA-B27 class I molecules in the same
vaccinia virus-infected cells.
Binding affinity of TAP-independent vaccinia virus ligands
for the B*2705 molecule. The A10L867-876 and K2L16-30 (but not
B8R53-59) peptides have the known anchor motifs for HLA-
B*2705 binding of Arg at P2 and basic or aliphatic C-terminal
residues (SYFPEITHI database [54]). As the B8R53-59 peptide was
also coimmunoprecipitated with an HLA-B27-specific MAb, it
could be an unusual HLA-B27-restricted ligand. To confirm that
HLA-B*2705 is the MHC class I molecule that presents these li-
gands,MHC-peptide complex stability assays were performed us-
ing TAP-deficient RMA-S cells transfected with the HLA-B*2705
molecule (Fig. 4). The two viral ligands with HLA-B27 anchor
motifs, A10L867-876 and K2L16-30, bound to HLA-B*2705 class I
molecules with EC50s to similar those of other natural high-
affinity ligands (Fig. 4B). In contrast, the HLA affinity was sub-
stantially lower for the B8R53-59 ligand, as suggested by the absence
ofHLA-B27 anchormotifs, and this peptide could be considered a
low-affinity ligand. These data confirm that the ligands detected in
vaccinia virus-infected cells were endogenously presented in asso-
ciation with the B*2705 molecule. In summary, either HLA-
A*0201 or B*2705 class I molecules can bind both high- and low-
affinity ligands derived from different vaccinia virus proteins.
Six vaccinia virus ligands were endogenously presented by
HLA-B51 and/or HLA-Cw1 class I molecules in human TAP-
deficient cells. Given that several TAP-independent viral ligands
were identified in association with either HLA-A*0201 or B*2705
class Imolecules (see above), we investigated the possibility of new
vaccinia virus ligands being presented by other HLA class I mole-
cules expressed in the same T2 cells. As in the previous two anal-
yses, six fragmentation spectra were found in the VACV-infected
FIG 3 HLA-A0201 stabilization assay with synthetic VACV ligands. (A) The stability of HLA-A0201-peptide complexes on the surface of RMA-S transfectant
cells was measured by flow cytometry. The indicated peptides were used at 200 M. The mAb used was PA2.1. (B) The titration curves for synthetic VACV
A17L9-17, A10L614-623, and A10L688-696 peptides with HLA-A0201 are depicted. The C4CON and KPNA2 peptides were used as negative and positive controls,
respectively. The results, calculated as fluorescence index values (see panel A), represent the means of the results of three or four independent experiments. The
calculated EC50s SD are shown in panel B.
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peptide pool that were absent from the uninfected control pool,
and these spectra were also resolved as peptides of vaccinia virus
proteins. Furthermore, a human proteome database search also
failed to identify these spectra as human protein fragments, con-
firming the viral origin of these HLA-bound peptides. Supple-
mental Fig. S4 and S5 show the experimentally obtained MS/MS
spectra and their respective assignments. Each putative peptidic
sequence was confirmed according to its identity with theMS/MS
spectrum of the corresponding synthetic peptide (see Fig. S4 and
S5 in the supplemental material). Five of these peptides, IAMKR
TLLEL (D5R148-157), LPFGSLGI (A50R294-301), IPSPGIMLV
(C11R101-110), MLDDFSAGAGVLDKDL (A17L9-25), and DGLI
IISI (D8L112-119), represented new viral sequences. Surprisingly,
the K2L16-30 ligand previously detected in association with HLA-
B*2705 (see Fig. S3 in the supplemental material) was also immu-
noprecipitated in the third roundwith theW6/32Ab. AsHLA-A2,
HLA-B51, and HLA-Cw1 present peptides with similar anchor
motifs (SYFPEITHI database [54]), HLA-peptide complex stabil-
ity assays were performed to confirm that the sequential immu-
noprecipitation was performed correctly and to exclude the pos-
sibility that residual HLA-A2-bound ligands that were not fully
immunoprecipitatedwith the PA2.1 (anti-HLA-A2)Ab in the first
round would be immunoprecipitated in the third round with the
W6/32 Ab (specific for amonomorphicHLA class I determinant).
Figure 5A shows that, in contrast to the positive-control KPNA2
peptide results, binding of HLA-A2 complexes to these six ligands
was not detected. Therefore, these viral ligands do not bind to
HLA-A2, which validates the experimental strategy used. In addi-
tion, to identify the HLA restriction of these ligands, new HLA-
peptide complex stability assays using TAP-deficient T2 cells with
specific anti-HLA-B or anti-HLA-C Abs were performed. The
numbers of HLA-peptide surface complexes induced by the IAM
KRTLLEL (D5R148-157), LPFGSLGI (A50R294-301), and IPSPG
IMLV (C11R101-110) synthetic peptides were similar to those in-
duced by a well-knownHLA-B51 ligand, HBVHBc19-27 (Fig. 5B),
by the use of the anti-HLA-B Ab, indicating that these peptides
were restricted by the HLA-B51 class I molecule. HLA stabiliza-
tion was detected using anti-HLA-C (Fig. 5C) Ab with IPSPG
IMLV (C11R101-110), MLDDFSAGAGVLDKDL (A17L9-25), and
DGLIIISI (D8L112-119), indicating that these peptides were re-
stricted by the HLA-Cw1 allele. In addition, the K2L16-30 ligand
also bound to HLA-B*2705 (see Fig. S3 in the supplemental ma-
terial and Fig. 4) presented efficient binding to HLA-Cw1 class I
molecule, justifying their dual immunoprecipitation (Fig. 5). Five
of these six viral ligands bound to HLA-B51 (Fig. 5D) or HLA-
Cw1 (Fig. 5E) class Imolecules with EC50s similar to those of other
natural high-affinity ligands. The only exception was the K2L16-30
peptide, which showed a substantially lower affinity for HLA-
Cw1, indicating that this peptide could be considered a low-
affinity ligand (Fig. 5E).
Thirteen natural peptide-HLA class I complexes were
formed simultaneously in the same infectedTAP-deficient cells.
A total of 11 viral ligands that bound to the four HLA class I
molecules expressed in the T2 cells were identified (summarized
in Table 2). Similar numbers (3 or 4) of ligands were identified in
association with HLA class I molecules previously described as
showing low (HLA-A2), high (HLA-B27), or unknown (HLA-B51
andHLA-Cw1) TAP dependency. The sameN-terminal core pep-
tide, MLDDFSAGA, was found in two different ligands, A17L9-17
and A17L9-25, bound toHLA-A2 andHLA-Cw1, respectively. Ten
sequences represented new vaccinia HLA ligands. Most were re-
stricted by a single HLA allele, but two ligands, K2L16-30 and
C11R101-110, were found to be associated with two different alleles
each, alleles HLA-B27 and HLA-Cw1 and alleles HLA-B51 and
HLA-Cw1, respectively. This implies that 13 different natural
peptide-HLA class I complexeswere formed simultaneously in the
same infected TAP-deficient cells.
Conservation of ligands amongmembers of theOrthopoxvi-
rus family.The sequences of 11 vaccinia virus ligands identified in
the WR strain were compared with homologs derived from vari-
FIG 4 HLA-B2705 stabilization assay with synthetic VACV ligands. (A) Stability of HLA-B2705-peptide complexes on the surface of RMA-S transfectant cells
measured by flow cytometry. The indicated peptides were used at 200 M. The mAb used was ME1. (B) The titration curves for synthetic VACV A10L867-876,
K2L16-30, and B8R53-59 peptides with HLA-B2705 are depicted. The C4CON and influenza virus (Flu) NP peptides were used as negative and positive controls,
respectively. The results, as in Fig. 2, represent the means of the results of four independent experiments.
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ous poxviruses. This comparison included the Copenhagen and
MVA strains of VACV, two strains of human poxvirus (variola
major and variolaminor), and othermammalian poxviruses, such
as camelpox, cowpox, ectromelia virus, horsepox, monkeypox,
rabbitpox, and taterapox. This study revealed a high degree of
conservation of the ligands among orthopoxviruses (Table 3). Ten
of these 11 ligands are almost fully conserved in the variola major
andminor viruses, with aminor substitution in the P7 position of
the C11R101-110 sequence. Only 60% of the previously described
TAP vaccinia virus epitopes are conserved in the variola pro-
teome (46, 50, 53), indicating that TAP-independent vaccinia li-
gands are more highly conserved between immunogenic and
pathological poxviruses than TAP-dependent epitopes.
Low hydrophobicity in TAP-independent vaccinia virus li-
gands. Eight TAP-independent epitopes, restricted by four differ-
ent HLA class I molecules, were previously characterized with re-
spect to their Epstein-Barr virus (EBV)CTL response (reviewed in
reference 38). For this virus, only peptides from the BRLF1 and
LMP2 proteins with high hydrophobicity are TAP independent
(37, 38). Therefore, we tested this correlation in our vaccinia virus
system. The hydrophobicity values for all TAP-independent EBV
epitopes were determined over a range that reached a maximum
of 2.1 on the grand average of hydropathicity (GRAVY) scale, with
the maximum value found for the EBV LMP2 LLWTLVVLL pep-
tide (Table 4). All three HLA-B*2705 ligands and the A10L614-623
HLA-A*0201-restricted ligand identified in our studywere hydro-
philic, with negative GRAVY values (Table 4). Only the vaccinia
virus HLA-Cw1-restricted D8L112-119 epitope, with a GRAVY
value of 2.1, was hydrophobic. The other six ligands showed low
positive GRAVY values, indicating low hydrophobicity (Table 4).
TheGRAVYmean value for these 11 vaccinia ligands was only 0.3,
which was very different from the value for the EBV epitopes and
similar to the value for the TAP-dependent vaccinia epitopes (Ta-
ble 4). These results show that hydrophobicity is not a necessary
condition for the TAP-independent presentation of ligands and
epitopes from other viruses such as vaccinia virus.
Recognition ofHLA-A*0201 ligands by specific CD8T cells
in HLA-transgenic mice immunized with vaccinia virus. To
study the immunogenicity of the identified HLA-A*0201 viral li-
gands, transgenic HLA-A*0201-positive mice were immunized
withVACV. Later, physiologicalmeasurement of the functional in
vivo activity of CD8T lymphocytes against HLA-A2 viral ligands
FIG 5 HLA class I stabilization assay of synthetic VACV ligands. (A, B, and C) The stability of HLA-A2 (A), HLA-B51 (B), and HLA-Cw1 (C) at the cell surface
of T2 TAP-deficient cells was measured by flow cytometry. The indicated peptides were used at 200 M. (D and E) Titration curves for the indicated synthetic
VACV peptides, immunoprecipitated with W6/32 Ab, with HLA-B51 (D) or HLA-Cw1 (E). The KPNA2 peptide was used as negative control (solid line). The
HBV HBc19-27 and CMV pp657-15 peptides were used as positive controls for binding to the HLA-B51 and HLA-Cw1 alleles, respectively. The Abs used were
monoclonal PA2.1 (anti-HLA-A2; see panel A), polyclonal H00003106-B01P (anti-HLA-B class I molecules; see panels B and D), and polyclonal SC-19438
(anti-HLA-C class I molecules; see panels C and E). The results, as in Fig. 2, represent the means of the results of four to six independent experiments.
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as identified bymass spectrometry was carried out. HLA-A*0201-
transgenic mice eliminated VACV peptide-pulsed CFSEhigh cells
when they had been previously immunized but not when unin-
fected control mice were used (Fig. 6). In addition, up to 30 days
postimmunization, polyclonal CTL lines were generated that were
monospecific for each HLA-A2 viral ligand identified by mass
spectrometry. These CTL lines specifically recognized peptide-
pulsed cells (Fig. 7), indicating that the HLA ligands were all
A*0201-restricted CTL epitopes and that they were simultane-
ously recognized as part of the long-term memory response to
vaccinia virus. Also, these CD8 effector lines specifically recog-
nized VACV-infected cells (Fig. 7D).
Several attempts to induceCTL responses to the identified viral
B*2705-restricted ligands in HLA-B*2705-transgenic mice were
unsuccessful. This was also the case for the influenza NP epitope
previously described in a study of influenza virus-infected B27
humans (67) that we used as a CTL-positive control. The mouse
model used carried HLA-B27 and endogenous murine H2 class I
molecules (28), in contrast to the HLA-A2-transgenic mouse
knockout used previously for these mouse molecules (52). This
may have reduced the efficiency of HLA-restricted Ag-specific re-
sponses to undetectable levels (11), although the possibility that
the T cell repertoire was a limiting factor could not be discounted.
Unfortunately, HLA-B27-transgenic mice deficient for H2 class I
expression (11) were not available. Therefore, the study of HLA-
B*2705-restricted CTL responses to vaccinia virus ligands was not
feasible.
Three different antigen-processing pathways were involved
in the presentation of A10L688-696 and A17L9-17 epitopes in in-
fected TAP-sufficient cells. To study the antigen-processing
pathways involved in the endogenous generation of the A10L688-
696 and A17L9-17 viral epitopes, we investigated the presentation of
these epitopes to specific CTLs in the presence of diverse protease
inhibitors in VACV-infected TAP-sufficient cells.
First, to demonstrate that these HLA-A2-restricted epitopes
required endogenous processing, their presentation was analyzed
in the presence of BFA. This drug blocks class I export beyond the
cis-Golgi compartment (39), thus preventing the surface expres-
sion of newly assembled HLA class I-peptide complexes from an
endogenous origin (Table 1 summarizes the specificity of all in-
hibitors used). The complete inhibition of specific lysis in both
specific CTL lines caused by the addition of BFA during vaccinia
infection (Fig. 8A) demonstrated that the two relevant epitopes
were indeed generated from proteins endogenously processed in
infected cells.
Lactacystin, a Streptomyces metabolite (19, 49), was used to
study the involvement of the proteasome in the presentation of
these epitopes. This drug had no effect on the specific recognition
TABLE 2 Summary of HLA molecules bound by vaccinia virus epitopes
Ligand Sequence MAb useda
Molecule detection resultb
HLA-A2 HLA-B27 HLA-B51 HLA-Cw1
A17L9-17 MLDDFSAGA PA2.1 c ND ND ND
A10L614-623 SPEGEETII PA2.1  ND ND ND
A10L688-696 ILDRIITNA PA2.1  ND ND ND
A10L867-876 SRGYFEHMKK ME1 ND  ND ND
B8R53-59 WQTMYTN ME1 ND  ND ND
K2L16-30 YRLQGFTNAGIVAYK ME1/W6-32    
D5R148-157 IAMKRTLLEL W6-32  ND  
A50R294-301 LPFGSLGI W6-32  ND  
C11R101-110 IPSPGIMLV W6-32  ND  
A17L9-25 MLDDFSAGAGVLDKDL W6-32  ND  
D8L112-119 DGLIIISI W6-32  ND  
a The MAbs used for the sequential immunoprecipitations were PA2.1 (specific for HLA-A2), ME1 (specific for HLA-B27), and W6-32 (specific for a monomorphic HLA-A, HLA-
B, or HLA-C determinant).
b ND, not done.
c Significant difference (P 0.001) compared with the negative control results.
TABLE 3 Conservation of viral HLA ligands in several orthopoxvirusesa
Poxvirus A17L9-17 (HLA-A2) A10L614-623 (HLA-A2) A10L688-696 (HLA-A2) A10L867-876 (HLA-B27) B8R53-59 (HLA-B27)
VACVWR MLDDFSAGA SPEGEETII ILDRIITNA SRGYFEHMKK WQTMYTN
VACV Copenhagen --------- --------- --------- ---------- -------
VACVMVA --------- --------- --------- ---------- -------
Variola major --------- --------- --------- ---------- -------
Variola minor --------- --------- --------- ---------- -------
Camelpox --------- --------- --------- ---------- -------
Cowpox --------- --------- --------- ---------- -------
Ectromelia virus --------- --------- --------- ---------- -------
Horsepox --------- --------- --------- ---------- -------
Monkeypox --------- --------- --------- ---------- -------
Rabbitpox --------- --------- --------- ---------- -------
Taterapox --------- --------- --------- ---------- -------
a The sequences used were obtained from the NCBI database (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
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by A10L688-696- or A17L9-17-specific CTLs of target cells infected
with VACV (Fig. 8A). Although the proteasome may be involved
in the antigen processing of these epitopes, these data suggest that
the lactacystin-inhibitable proteasome activity is not absolutely
required.
Because several endogenous TAP-independent HLA-2 class I
ligands are derived from cleavage of the signal sequences gener-
ated by the signal peptidase (SPase) complex (36, 70) and because
no specific inhibitor of this enzymatic activity was available, the
involvement of the SPase complex in A17L9-17 ligand production
could not be studied directly. SPase-processed peptides need fur-
ther cleavage by signal peptide peptidase (SPPase) (42, 68, 69).
Therefore, the involvement of SPPase in antigen presentation was
tested by treating target cells with the SPPase-specific inhibitor
(z-LL)2 ketone (68, 69). In similarity to lactacystin results, the
inhibition of specific presentation was not detected with this drug
(Fig. 8A).
To identify proteases distinct from the proteasomes that could
contribute to antigen processing of bothHLA-A2 epitopes, exper-
iments with several specific protease inhibitors were performed.
Leupeptin (LEU) (65), pepstatin (PEPST) (34, 65) and 1,10-
phenanthroline (PHE) (34, 64) were initially tested because they
specifically inhibit different protease families (Table 1), thereby
covering a wide range of proteases. Figure 8A shows that these
three inhibitors had no effect on the specific recognition of target
cells infected with VACV. In addition, because the activity of
ERAAP, an enzyme involved in antigen processing (59, 72), is not
fully blocked by PHE at the concentration used in this study, leu-
cinethiol (LeuSH) (Table 1) (61) was also included. Like the other
protease inhibitors, LeuSH did not inhibit the recognition of in-
fected cells (Fig. 8A), indicating that ERAAP cannot be involved in
the generation of these TAP-independent epitopes.
In summary, the inhibitors used did not block the presentation
of the two viral epitopes tested. The two most likely explanations
for these results are as follows. First, these epitopes could have
been processed by a protease(s) that was not blocked by the col-
lection of inhibitors used in Fig. 8A. This explanation is not likely,
because the inhibitors were chosen to cover a wide range of pro-
tease classes. Alternatively, these epitopes could have been inde-
pendently processed in parallel by different proteases, meaning
that the different antigen-processing pathways would need to be
inhibited at the same time to produce an effect. To test this hy-
pothesis, the effects of combinations of several inhibitors on anti-
gen presentation in vaccinia virus-infected cells were tested.
Because most class I epitopes are generated by proteasome
activity, the presentation of these epitopes was analyzed in the
presence of lactacystin, together with each other inhibitor in
turn. Figure 8B shows that the combination of lactacystin with
(z-LL)2 ketone, LEU, or PEPST did not block presentation in
infected cells. In contrast, a partial blocking of presentation
was observed in target cells treated with lactacystin and PHE
(Fig. 8B). These results demonstrate that the A10L688-696 and
A17L9-17 peptides were processed by bothmetalloproteases and
proteasomes in vivo. Additionally, the antigen presentation of
both epitopes was partially inhibited by the combination of
lactacystin and LeuSH, indicating that ERAAP or other metal-
loaminopeptidases were involved in the generation of these
viral epitopes. Metallopeptidases can be divided into amino-
peptidases, endopeptidases, carboxypeptidases, and carboxy-
dipeptidases, among other peptidase categories, based on their
cleavage mechanisms (reviewed in reference 55). Some of these
groups can be distinguished by the use of different specific
inhibitors (summarized in Table 1). To more precisely identify
the metallopeptidase group involved in both A10L688-696 and
A17L9-17 antigen processing, target cells were infected with
VACV and treated with a mixture of lactacystin and different
specific inhibitors (Table 1). The caspase-1-specific inhibitor
z-VAD.fmk was also included in view of the sensitivity of this
cysteine protease to PHE. Remarkably, none of the different
combinations of inhibitors tested prevented antigen presenta-
tion to specific CTLs (Fig. 8B). Because phosphoramidon is
able to inhibit bacterial endopeptidases but does not block all
metalloendopeptidases of mammalian origin, the most likely
explanation for our results is that mammalian metalloendo-
peptidases that are not blocked by phosphoramidon are in-
volved in the antigen processing of these viral epitopes. Over
100 different well-characterized metalloendoproteases of
higher vertebrates are resistant to this drug (7); therefore, pos-
itive identification of the peptidase involved the processing of
TAP-independent vaccinia epitopes awaits further character-
ization.
To demonstrate that two different types of metalloproteases,
aminopeptidases and endopeptidases, were independently in-
volved in the generation of the A10L688-696 and A17L9-17 epitopes,
their presentation was analyzed in the presence of a mixture of
PHE and LeuSH. The incomplete blocking detected in the presen-
tation indicated that aminometalloproteases and metalloendo-
peptidases are independently needed to process both the
TABLE 3 Continued
K2L16-30 (HLA-B27, -Cw1) D5R148-157 (HLA-B51) A50R294-301 (HLA-B51) C11R101-110 (HLA-B51, -Cw1) A17L9-25 (HLA-Cw1) D8L112-119 (HLA-Cw1)
YRLQGFTNAGIVAYK IAMKRTLLEL LPFGSLGI IPSPGIMLV MLDDFSAGAGVLDKDL DGLIIISI
--------------- ---------- -------- --------- ---------------- --------
--------------- ---------- -------- --------- ---------------- --------
--------------- ---------- -------- ------V-- ---------------- --------
--------------- ---------- -------- ------V-- ---------------- --------
--------------- ---------- -------- ------V-- ---------------- --------
--------------- ---------- -------- ------V-- ---------------- --I--VA-
--------------- ---------- -------- --------- ---------------- --------
--------------- ---------- -------- --------- ---------------- --------
--------------- ---------- -------- ---L--V-- ---------------- --I---A-
--------------- ---------- -------- ------V-- ---------------- --------
--------------- ---------- -------- ------V-- ---------------- --------
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A10L688-696 and A17L9-17 epitopes (Fig. 8B). Finally, the recogni-
tion of infected cells by specific CTLwas abrogated in the presence
of three inhibitors: lactacystin, PHE, and LeuSH (Fig. 8B). To
exclude the possibility that the inhibitory effect of lactacystin,
PHE, or LeuSH was due to toxic effects on target cells or on re-
combinant vaccinia virus (rVV) replication rather than to a spe-
cific blocking of the respective proteases, experiments similar to
those shown in Fig. 8B were performed in parallel using the same
target cells and VACV-OVA257-264, which codes for the minipro-
tein MSIINFEKL. Specific recognition by SIINFEKL-specific
CTLs of target cells infected with the VACV-OVA257-264 virus
(64% 11% of CD8 cells secreted IFN-) was detected. In con-
trast, VACV-OVA257-264-infected target cells incubated with all
combinations of these three inhibitors were efficiently recognized
by SIINFEKL-specific CTL and no inhibition was detected
(hatched bars in Fig. 8B). These data indicate that inhibition of the
A10L688-696 andA17L9-17 epitopes by addition of lactacystin, PHE,
and LeuSH drugs is formally due to specific blockage of the re-
spective proteases and not to blocking of rVV replication or other
toxic effects.
In summary, the proteasomes, aminometalloproteases, and
metalloendopeptidases are all independently involved in the anti-
gen processing of both A10L688-696 and A17L9-17 epitopes. The
existence of identical neighboring residues around both the
A10L688-696 and A17L9-17 sequences (Fig. 8C) could explain
the similarity of the antigen-processing pathways identified in
these two different HLA-restricted epitopes.
DISCUSSION
The results reported here show an exceptional diversity of TAP-
independent ligands, with 11 ligands simultaneously processed
and presented as part of 13 different HLA-peptide complexes in
VACV-infected cells. All three of the identified HLA-A2 ligands
generated long-termCTLmemory responses to vaccinia virus in a
transgenic mousemodel. Proteasomal and nonproteasomal path-
ways were involved in the processing and presentation of two
vaccinia virus-encoded HLA-A2-restricted antigens.
Identification of viral HLA ligands by mass spectrometry anal-
ysis contributes to a better understanding of the cellular antiviral
immune response. However, the mass spectrometry strategies de-
signed to identify such ligands have not become routine because of
the difficulty in selecting and identifying the very limited number
of viral sequences among the large number of self-peptides bound
to HLA class I molecules. Therefore, the number of studies on
viral HLA ligands is still limited. To date, only two studies have
identified vaccinia virus ligands by mass spectrometry (26, 46).
Here, we identified three to four TAP-independent ligands that
were processed and presented by each of the four class I molecules
expressed in infected cells. Neither HLA-specific elution nor CTL
responses have previously been reported in TAP cells for 10 of
the ligands identified in our study. However, as all three TAP-
independent HLA-A*0201 ligands also generated responses in
TAP HLA-A*0201-transgenic mice, these epitopes must also be
generated in wild-type cells.
We detected HLA ligands from viral gene products expressed
in the three gene expression temporality clusters of the viral life
cycle (see Table S1 in the supplemental material), namely, the
early (A50R, B8R, C11R, and D5R), early/late (K2L), and late
(A10L, A17L, and D8L), in agreement with a previous study in-
vestigating the CTL response in the same virus strain (53). In
TABLE 4 TAP-independent ligands and epitopes and their hydrophobicity
Ligand(s) or epitope(s) Protein Virus Hydrophobicitya Reference(s) or source
LLWTLVVLL LMP2 EBV 2.9 38
CLGGLLTMV LMP2 EBV 2.1 38
8 TAP epitopes (mean SD) EBV 2.5 0.2 38
MLDDFSAGA A17L9-17 Vaccinia virus 0.4 This study
SPEGEETII A10L614-623 Vaccinia virus 0.6 This study
ILDRIITNA A10L688-696 Vaccinia virus 0.8 This study
SRGYFEHMKK A10L867-876 Vaccinia virus 1.7 This study
WQTMYTN B8R53-59 Vaccinia virus 1.2 This study
YRLQGFTNAGIVAYK K2L16-30 Vaccinia virus 0.1 This study
IAMKRTLLEL D5R148-157 Vaccinia virus 0.7 This study
LPFGSLGI A50R294-301 Vaccinia virus 1.5 This study
IPSPGIMLV C11R101-110 Vaccinia virus 1.6 This study
MLDDFSAGAGVLDKDL A17L9-25 Vaccinia virus 0.3 This study
DGLIIISI D8L112-119 Vaccinia virus 2.1 This study
11 TAP ligands (mean SD) (P 0.0001) Vaccinia virus 0.3 1.2 This study
79 TAP epitopes (mean SD) Vaccinia virus 0.4 1.0 26, 46
a Values correspond to the grand average of hydropathicity (GRAVY) scale (ProtParam tool [ExPASy Proteomics Server; http://www.expasy.ch).
FIG 6 In vivo killing activity of VACV peptide-specific CTLs in HLA-A0201-
transgenic mice. HLA-A0201-transgenic mice were infected i.p. with VAVC.
One week later, they were injected i.p. with syngeneic splenocytes that were
either labeled with a low level of CFSE and not subjected to pulsing or pulsed
with the indicated VACV peptides and labeled with a high level of CFSE. Two
days later, the remaining CFSE-labeled target cells in the peritoneal cavity were
lavaged and analyzed by flow cytometry. Percent in vivo lysis values for indi-
vidual animals (circles) SD (lines) are shown.
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similarity to the TAP response, the TAP-independent response
also sampled proteins from the entire viral life cycle of the VACV
WR strain. Other authors reported the absence of presentation of
peptides derived from late viral Ags to specific T cells by infected
mouse target cells (29, 46), but a differentVACV strainwas used in
their studies. The sequences we identified were derived from eight
different vaccinia virus proteins (see Table S1 in the supplemental
material). Five of the proteins present signal sequence or trans-
membrane domains in their respective amino acid sequences and
are therefore accessible to HLA-containing compartments where
they could be processed by resident proteases. In contrast, for
three vaccinia virus proteins, A10L, A50R, and D5R, no obvious
TAP-independent antigen presentation could be predicted. How-
ever, vaccinia virus DNA replication is associated with the cyto-
plasmic side of the rough ER, and when the replication proceeds,
ER membranes are recruited (reviewed in reference 60). Late in
infection, the ER envelope is disassembled, and these membranes
are recycled to the ER (reviewed in reference 60). During this
complex process, which includes deep membrane reorganization,
some molecules of A10L, A50R, and D5R proteins could gain ac-
cess to a TAP-independent antigen-processing pathway.
In most cases, the identified natural MHC class I ligands had
the canonical anchor motifs, and their respective antigenicity and
MHC class I binding affinity data were correlated. This suggests
that only high-affinity peptides are recognized by CTLs and that
epitopes of low affinity may be immunologically irrelevant. We
have demonstrated that cytotoxic responses are targeted against
both high- and low-affinity HLA-A*0201 ligands of VACV; there-
fore, theTCRs of individual CTLs specific for low-affinity epitopes
must display a compensatory high affinity. In addition, it has been
reported that low-affinity self-peptides in autoimmunity (re-
viewed in reference 16) or tumor peptides (4) generate specific
responses. These findings suggest that the range of peptides that
can generate CTLs is broader than was formerly thought and that
the role of low-affinity epitopes in antiviral responses must be
evaluated in future studies.
DifferentMHC class I alleles have different TAP dependencies.
The widespread HLA-A2 allele is considered to be the least TAP
dependent (63). Alleles such as HLA-B7 and HLA-B8 can also
bind ligands that are dependent on mechanisms other than TAP
transport, while otherMHC class I molecules, includingHLA-A3,
HLA-A24, and HLA-B27, have been described as mainly TAP de-
pendent (2). In the present report, several TAP-independent li-
gands were identified for alleles with different TAP requirements.
Thus, the overall expression of MHC class I molecules with en-
dogenous bound peptides is not indicative of specific TAP-
independent cellular responses, which must be studied individu-
ally for each specific virus.
FIG 7 Recognition by CTLs of VACV epitopes presented by the HLA-A0201 class I molecule. (A to C) RMA-HLA-A0201 target cells prepulsed with 105 M
A17L9-17 (A), A10L614-623 (B), andA10L688-696 (C) synthetic peptides (filled squares) were tested in a cytolytic assaywith their respectivememory peptide-specific
CTL lines obtained fromHLA-A0201-transgenic mice immunized up to 30 days before with VACV (upper panels). Negative controls used were unpulsed cells
(open squares) and pulsed cells with the KPNA2 peptide (open circles). The data represent themeans of the results of at least three independent experiments. (D)
HLA-A0201 TAP cells were infected with VACV (open bars) or not (filled bars) at a multiplicity of infection of 40 PFU/cell and analyzed by ICS for CD8 T
cell activation with the HLA-A0201 memory peptide-specific CTL lines. The data represent the means of the results of 4 to 6 independent experiments.
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Although TAP-independent viral epitopes are known (re-
viewed in references 13, 27, and 36), only one epitope has been
identified as the target of a specific antiviral CTL response inmost
of the cases studied. No systematic studies of TAP-independent
pathways with a single virus and different HLA molecules have
been reported. The exception is EBV, for which CTLs from differ-
ent donors recognize several viral epitopes from twodifferent viral
proteins restricted by several HLA class I molecules in TAP-
negative cell backgrounds (reviewed in reference 38). Here, we
report a second case with 11 ligands from eight different viral
proteins presented by four different HLA class I molecules in the
same TAP-deficient vaccinia virus-infected cells. The simultane-
ous presentation of the elements of this broad complexity of viral
peptide-MHC complexes can help to explain why TAP-deficient
patients do not seem particularly susceptible to viral infections
and may appear asymptomatic for long periods of their lives. In
addition, the existence of multiple TAP-independent ligands in two
very different viruses, a gammaherpesvirus and an orthopoxvirus,
suggests that thesepathways could represent anextendedbutperhaps
secondary mechanism that forms part of the multiple layers of de-
fense against viral infection and that the significance of these alterna-
tive processing pathways in vivo needs to be further studied.
The involvement of the following proteases in the processing of
endogenously synthesized antigens in a manner independent of
that seen with the classical proteasome pathway has been reported
previously (reviewed in reference 12). In the present study, two
HLA-A2-restricted epitopes were processed in parallel by amino-
metallopeptidases as well as bymetalloendoproteases and a classic
proteasomal pathway.
In addition to the A17L9-17 epitope previously described in a
study performed using TAP-sufficient cells (5), two distinct pep-
tide epitopes recognized by human HLA-A2-restricted CD8 T
FIG 8 Recognition of target cells infected in the presence of inhibitors. (A and B) RMA-HLA-A0201 target cells infected for 16 h with VACV or
VACV-OVA257-264 at a multiplicity of infection of 40 PFU/cell were treated with the indicated inhibitors. An ICS assay was used to test for recognition by
A10L688-696-specific (open bars), A17L9-17-specific (closed bars), or SIINFEKL-specific (hatched bars) CTLs. The percentages of specific inhibition
obtained by the addition of the indicated single inhibitor (A) or mixture of two or three inhibitors (B) were calculated as follows:
% specific inhibition  100 
ICS VAVC inhibitor  ICS without infection
ICS VACV ICS without infection 	 100
where the data displayed represent the means  SD of the results of 4 to 6 independent experiments. (C) The sequences of the residues neighboring the
epitopes in A10L and A17L proteins. The sequence of each epitope is boxed. Residues that are identical in the two sequences are indicated with boldface
characters. LC, lactacystin.
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cells and eight HLA-B27, HLA-B51, and/or HLA-Cw1 ligands
were newly detected in this study. Nine of the viral ligands identi-
fied are conserved in all three vaccinia virus strains, seven or-
thopoxviruses (including cowpox virus), and two variola strains.
In contrast, only 60% of the previously described vaccinia virus
epitopes in the variola virus proteome are identical (46, 50, 53).
Therefore, TAP-independent vaccinia ligands are more highly
conserved between immunogenic and pathological poxviruses
than TAP-dependent epitopes and could be more specific targets
for immunization. Cowpox virus, the first component of early
vaccines, specifically inhibits TAP-dependent peptide transloca-
tion (1); therefore, TAP-independent epitopes conserved between
variola virus and cowpox virus are probably responsible for the
initial cross-protection. Additionally, truncated gene fragments
similar to those encoding the TAP-blocking CPXV12 protein are
widely found in poxvirus genomes (Poxvirus Bioinformatics Re-
sources Center; http://www.poxvirus.org) and frequently repre-
sent loss-of-function phenotypes, but this “genetic debris” may
acquire entirely new, unanticipated functions. Therefore, the con-
servation of epitopes between different vaccine strains and patho-
gens is relevant for vaccine design and suggests that ligands from
TAP-independent pathways could be interesting candidates for
inclusion in immunization protocols. This idea is also important
with respect to bioterrorism, because some countries did not par-
ticipate in the WHO smallpox eradication program and, at this
time, no information about the elimination of their samples of the
pandemic virus has been provided.
Computational methods designed for predicting MHC-
peptide binding are increasingly being used to identify epitopes
for vaccine design and to monitor T cell responses (reviewed in
references 35 and 44). The prediction of MHC-peptide binding is
far from perfect, as our results indicate. The prediction by bioin-
formatics tools of HLA class I molecules presenting the nine vac-
cinia virus ligands identified in the current study showed several
different mistakes, including incomplete HLA identifications
(K2L16-30 and C11R101-110 ligands), ambiguous HLA restrictions
(D5R148-157 and A17L9-25 ligands), and wrong assignations
(A10L614-623 andD8L112-119 ligands) (Table 5). In summary, more
than half of these ligands showed inconsistencies between the
computational predictions and experimentally detected HLA re-
striction. These results reveal the limitations of predictive meth-
ods for identifying naturalMHCclass I ligands andT cell epitopes.
The current analytical algorithmsmay not be sufficiently accurate
and should be used with caution.
Collectively, the results in the current report highlight the im-
portance of analyzing natural peptides that result from the endog-
enous processing of viral proteins and demonstrate the complex-
ity and plasticity of MHC-peptide interactions. This analysis is of
fundamental importance for gaining a detailed understanding of
MHC class I-restricted immunity and for future vaccine design.
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